Korean J Head Neck Oncol.
2022 May;38(1):1-9. 10.21593/kjhno/2022.38.1.1.
Recent Improvements in the Treatment of High-Risk Thyroid Cancer
- Affiliations
-
- 1Division of Endocrinology, Center for Thyroid Cancer, National Cancer Center, Goyang, Korea
- KMID: 2530559
- DOI: http://doi.org/10.21593/kjhno/2022.38.1.1
Abstract
- Thyroid cancer is one of the slow-growing tumors with excellent oncological outcomes. However, a small set of patients with unexpectedly severe outcomes are usually ignored. Anaplastic thyroid cancer (ATC) remains one of the most aggressive and lethal solid tumors. Recently, dabrafenib and trametinib combination therapy or neoadjuvant BRAF induction therapy has shown promising results. In addition, a combination of targeted drugs, immunotherapy, surgery, and radiation therapy can improve overall survival in ATC patients. Another disease for which there is no breakthrough treatment is radioactive iodine-refractory differentiated thyroid cancer (DTC). To date, multikinase inhibitors (sorafenib, lenvatinib) targeting the growth factor signaling pathway have been developed and approved as anticancer agents for patients with advanced DTC. This review includes results from multikinase inhibitors to the emergence of new target molecules, including rearrangements during transformation (RET) and tropomyosin receptor kinase (TRK).
